Stay updated with breaking news from Biotech investing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ABBVie Inc. between April 30, 2021 and August 31, 2021, inclusive of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO . ....
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to youABBV Shareholders Click Here: Shareholders Click Here: . ....
Bristol Myers Squibb today announced that the company will take part in a fireside chat at Bernstein’s 38 th Annual Strategic Decisions Conference in New York, New York on Thursday, June 2, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer and Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development will answer questions about the company at 8:00 a.m. ET. . ....
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to youVLTA Shareholders Click Here: Shareholders Click Here: . ....
ABBVie and Gedeon Richter Plc. today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. ABBVie and Richter have collaborated . ....